The definition of remission in psoriatic arthritis: Can this be accurate without assessmen of multiple domains?

Annals of the Rheumatic Diseases

Volumn 74, Issue 12, 2015, Pages e66-

  Helliwell, Philip S ^a   Coates, Laura C ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 12; INTERLEUKIN 17; INTERLEUKIN 23; TUMOR NECROSIS FACTOR INHIBITOR;

CLINICAL DECISION MAKING; CLINICAL PRACTICE; COMPOSITE PSORIATIC DISEASE ACTIVITY INDEX; DISEASE ACTIVITY; DISEASE ACTIVITY IN PSORIATIC ARTHRITIS SCORE; DISEASE CLASSIFICATION; ENTHESITIS; HUMAN; LETTER; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; PSORIATIC ARTHRITIS DISEASE ACTIVITY SCORE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFERENCE VALUE; REMISSION; SEVERITY OF ILLNESS INDEX;

ARTHRITIS, PSORIATIC; HUMANS; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX;

EID: 84954370971     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-208509     Document Type: Letter

References (11)

1. Schoels MM, Aletaha D, Alasti F, et al. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. Ann Rheum Dis Published Online First: 12 Aug 2015 doi:10.1136/annrheumdis-2015-20750
2. Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167-70.
3. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).[erratum appears in Arthritis Rheum 2005;52:2951]. Arthritis Rheum 2005;52:1227-36.
4. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
5. Coates LC, Moverley AR, McParland L, et al. Results of a randomised controlled trial comparing tight control of early psoriatic arthritis (TICOPA) with standard care: tight control improves outcome. Lancet in press.
6. Kavanaugh A, Fransen J. Defining remission in psoriatic arthritis. Clin Exp Rheumatol 2006;24(6 Suppl 43):S-83-7.
7. Mumtaz A, Gallagher P, Kirby B, et al. Development of a preliminary composite disease activity index in psoriatic arthritis. Ann Rheum Dis 2011;70:272-7.
8. Helliwell PS, Fitz Gerald O, Fransen J, et al. The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). Ann Rheum Dis 2013;72:986-91.
9. Gossec L, Smolen JS, Gaujoux-Viala C, et al. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis 2012;71:4-12.
10. Coates LC, Fitz Gerald O, Gladman DD, et al. MDA criteria for PsA show good correlation with physician and patient opinion and proposed composite measures. Ann Rheum Dis 2012;71(Suppl 3):575.
11. Taylor WJ, Fellow DE, Helliwell PS. Case definition of psoriatic arthritis. Lancet 2000;356:2095; author reply 6.